Consistent with our visual scoring approach, median PD-L1 positivity of 0.08% served as a prognostic cut-off for prediction for higher risk for tumor recurrence (RFS) (p = 0.033; Fig. 1H). This evidence concerns the gene CD274 and neoplasm.